Semaglutide: The Intake Side, Measured at Scale

The short version

Semaglutide (Ozempic, Wegovy, Rybelsus) is an approved prescription medicine, which sets it apart from everything else on this desk. It copies a gut hormone called GLP-1 — one of the signals the intestine releases after a meal to say that food has arrived — and it is re-engineered so that it survives in the bloodstream for about a week instead of a couple of minutes.

Its effect on weight is an appetite effect. The peptide reaches appetite circuits in the hypothalamus and brainstem, turns up the neurons that end a meal, turns down the ones that start one, and slows how fast the stomach empties. The published mechanism is explicit that food intake falls without a fall in energy expenditure — one side of the balance, not both.

The evidence base is the largest here. In STEP 1, once-weekly semaglutide 2.4 mg produced a mean body-weight change of -14.9% at 68 weeks against -2.4% on placebo ^[16]. In SELECT, across 17,604 adults with cardiovascular disease and no diabetes, it cut major adverse cardiovascular events by a fifth ^[15]. In FLOW, in 3,533 adults with type 2 diabetes and chronic kidney disease, it cut major kidney-disease events by about a quarter ^[14].

Doses named here describe what a trial administered. Nothing on this page is medical advice, and no dose is recommended for any person.

What it is

Semaglutide is a 31-amino-acid acylated analogue of human glucagon-like peptide-1, sharing roughly 94% sequence homology with the native hormone. Two backbone substitutions buy it protease resistance: at position 8, alanine is replaced by alpha-aminoisobutyric acid, which blocks cleavage by dipeptidyl peptidase-4; at position 34, lysine is replaced by arginine. The single remaining lysine at position 26 carries a C18 fatty di-acid side chain attached through a glutamic-acid/ADO spacer.

That lipid tail is the whole engineering trick. It binds the peptide strongly and reversibly to serum albumin, which shields it from renal clearance and enzymatic metabolism and is the structural basis for once-weekly administration. Native GLP-1 circulates for around two minutes; the analogue circulates on the order of a week.

An oral formulation exists as well, co-formulated with the absorption enhancer SNAC. Its oral bioavailability is very low, so the tablet form is administered fasted, with a small amount of water and separated from other food, drink and oral medication — a formulation requirement rather than a safety warning, but one that materially changes how much drug is absorbed.

Regulatory position: FDA-approved across several indications and formulations — type 2 diabetes mellitus, chronic weight management, reduction of major adverse cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and, since 2025, metabolic dysfunction-associated steatohepatitis. It is available as a once-weekly subcutaneous injection and a once-daily oral tablet. Compounded or non-pharmaceutical material falls outside that approved-product evidence base and carries documented quality and safety concerns.

How it works

Semaglutide is a long-acting agonist at the GLP-1 receptor, and its documented actions split cleanly into a pancreatic set and a central set.

In the pancreas, it potentiates glucose-dependent insulin secretion from beta cells and suppresses inappropriate glucagon release from alpha cells. Glucose-dependence is the safety-relevant detail: the insulin signal scales with circulating glucose, which is why the class does not behave like exogenous insulin.

In the gut, it slows gastric emptying, which contributes both to post-meal glucose control and to the sensation of fullness — and, in the same movement, to most of the gastrointestinal side effects the class is known for.

In the brain, which is where the weight effect actually lives, it reaches hypothalamic and brainstem appetite circuits — notably the arcuate nucleus and the area postrema — activating anorexigenic POMC/CART neurons and inhibiting orexigenic NPY/AgRP neurons. Food intake falls and food preference shifts. The published mechanism specifies that this happens without lowering energy expenditure.

Documented receptor targets span beta-cell and alpha-cell GLP-1 receptors, the hypothalamic arcuate nucleus, the brainstem area postrema and parabrachial nucleus, gastric smooth muscle and vagal afferents, and cardiovascular and renal GLP-1 receptors — the last of which is the mechanistic context for the outcome trials below.

What the research shows

STEP 1, weight, 68 weeks (2021). In 1,961 adults with overweight or obesity and without diabetes, once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight change of -14.9% from baseline against -2.4% on placebo — a treatment difference of about 12.4 percentage points ^[16].

SELECT, cardiovascular outcomes (2023). In 17,604 adults with established cardiovascular disease and a BMI of at least 27 but without diabetes, once-weekly semaglutide 2.4 mg reduced the primary composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, hazard ratio 0.80 (95% CI 0.72-0.90; P<0.001) — a 20% relative risk reduction ^[15]. This is the trial that moved the class from a metabolic story to an outcomes story.

FLOW, kidney outcomes (2024). In 3,533 adults with type 2 diabetes and chronic kidney disease, once-weekly semaglutide 1.0 mg reduced major kidney-disease events — kidney failure, a fall in eGFR of 50% or more, or kidney or cardiovascular death — with a hazard ratio of 0.76 (95% CI 0.66-0.88), a 24% lower risk than placebo ^[14].

SURMOUNT-5, head to head (2025). In 751 adults with obesity, tirzepatide (Mounjaro, Zepbound) produced greater mean weight loss than semaglutide at 72 weeks: -20.2% against -13.7%, a gap of about 6.5 percentage points, P<0.001 ^[13]. Recorded here because it is the cleanest available evidence that additional receptor engagement translates into additional weight loss — the premise on which retatrutide is built.

Safety synthesis (2021). A dedicated safety review concluded an overall favourable risk-benefit profile in type 2 diabetes, with mostly mild-to-moderate transient gastrointestinal effects — nausea in roughly one-third of patients — an increased risk of biliary disease, and pancreatic and thyroid-cancer signals for which definitive conclusions cannot yet be drawn given low incidence. It also advises retinopathy monitoring where glycaemia is corrected rapidly ^[17].

Reported effects, cautions & safety

The first block below is anecdotal, not clinical evidence — patient-review and community reports, unverified, with no quantities attached and no clinical adjudication behind them. They are recorded because they describe texture that trial tables do not, and for no stronger purpose than that.

Frequently reported as benefits. The single most common description is that the constant background chatter about food goes quiet, often within the first weeks; reporters describe filling up faster, eating a fraction of former portions, and no longer thinking about the next meal. Sharply reduced sugar cravings come next, often with fried and greasy food losing its appeal or becoming actively off-putting. Weight loss itself is described as steady and substantial over months, with the pace slowing after an early period. Commonly reported: improved blood-sugar readings among people using it for type 2 diabetes. Occasionally reported: a fading desire to drink alcohol.

Frequently reported as adverse. Nausea leads, sometimes with vomiting, peaking early and after each step up, and flaring after large or fatty meals. Commonly reported: foul sulfur-smelling burps, often with bloating; disrupted bowels in both directions, sometimes alternating; and tiredness in the first days after administration. Occasionally reported: reflux and heartburn; food aversions, a metallic taste and heightened smell sensitivity; headaches and light-headedness often linked by reporters to low fluid or food intake; hair shedding and facial gauntness a few months in, which reporters generally attribute to the speed of weight loss rather than to the drug; and minor injection-site redness or itching.

The documented cautions come from trials, labelling and pharmacovigilance.

• Gastrointestinal intolerance, especially during escalation. Nausea, vomiting, diarrhoea and constipation dominate the adverse-effect profile and are the leading cause of discontinuation; nausea affected roughly one-third of patients in the safety review, and the effects were predominantly mild to moderate and transient, concentrated around titration ^[17]. The slowed gastric emptying behind them is part of the mechanism, not an accident of it.
• Medullary thyroid carcinoma and MEN-2 history. The class carries a boxed warning derived from rodent C-cell tumours at supratherapeutic exposures; a personal or family history is treated as a contraindication. Human data have not established a clear increase in thyroid cancer, and the signal is properly described as unconfirmed in people ^[17].
• Acute pancreatitis. A class warning; treatment is conventionally stopped where pancreatitis is suspected. Pancreatic-cancer signals remain ones on which conclusions cannot yet be drawn owing to low incidence ^[17].
• Gallbladder and biliary disease. An increased risk of cholelithiasis is documented, attributed largely to the rate and magnitude of weight loss rather than to direct drug toxicity ^[17].
• Pre-existing diabetic retinopathy. Retinopathy complications were more frequent among patients with pre-existing retinopathy undergoing rapid correction of HbA1c; the leading interpretation is early worsening driven by the speed of that correction, and monitoring is advised in that setting ^[17].
• Lean mass. Body-composition substudies record that a meaningful proportion of the weight lost is lean tissue, which is the basis of a sarcopenia concern in older adults and of continuing research into protein intake and resistance training.
• Weight regain after stopping. Trial extensions and randomised-withdrawal designs both show substantial regain and reversion of cardiometabolic improvements after discontinuation, which frames this pharmacology as chronic rather than curative.
• Hair shedding. A pharmacovigilance reporting signal for alopecia exists and is most consistent with rapid-weight-loss-associated telogen effluvium, a reversible diffuse shedding, rather than direct drug toxicity.
• Pregnancy. Contraindicated per approved labelling, with a washout advised well ahead of a planned pregnancy because of the long elimination half-life.
• Oral formulation and narrow-therapeutic-index drugs. The tablet requires strict fasted administration to be absorbed at all. A systematic review of interactions with oral medicines found that delayed gastric emptying does not generally cause clinically significant interactions, but advised monitoring for narrow-therapeutic-index oral drugs during escalation.

Where it fits in energy balance

Semaglutide is the clean case of a single-lever compound. It moves intake, and the published mechanism states specifically that it does so without lowering energy expenditure — a detail worth dwelling on, because a common failure mode of dieting is that expenditure falls as intake does. A drug that reduces intake while leaving expenditure alone is, in energy-balance terms, doing something different from restriction.

What one lever buys is visible in the trial record: -14.9% at 68 weeks in STEP 1 ^[16], and outcome results at a scale nothing else on this desk approaches, from cardiovascular events in 17,604 adults ^[15] to kidney endpoints in 3,533 ^[14]. Depth of evidence, not breadth of mechanism, is this compound's distinguishing feature.

What one lever does not buy is visible in the head-to-head. Adding a second receptor arm beat it by about 6.5 percentage points at 72 weeks ^[13], and retatrutide — which adds a third arm acting on expenditure — reached -24.2% in its Phase 2 obesity trial ^[9]. The trade is the usual one in this literature: the compound with the most receptors has the least long-term evidence, and the compound with the most evidence has the fewest receptors. MOTS-c sits outside that trade entirely, acting inside the cell with no human efficacy trial behind it at all. The side-by-side page sets out the comparison in full.